Literature DB >> 19171800

Accelerated metabolism of voriconazole and its partial reversal by cimetidine.

Brad Moriyama1, Jason Elinoff, Robert L Danner, Juan Gea-Banacloche, Gennethel Pennick, Michael G Rinaldi, Thomas J Walsh.   

Abstract

We report a case of accelerated metabolism of voriconazole during therapy for invasive pulmonary aspergillosis, resulting in subtherapeutic levels. Target voriconazole levels were restored with high dosages of voriconazole (up to 40 mg/kg of body weight/day) and the addition of cimetidine as a cytochrome P450 enzyme inhibitor.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19171800      PMCID： PMC2663057          DOI： 10.1128/AAC.01221-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Modulation of drug metabolism in infectious and inflammatory diseases.

Authors:  H Iber; M B Sewer; T B Barclay; S R Mitchell; T Li; E T Morgan
Journal:  Drug Metab Rev       Date:  1999-02       Impact factor: 4.518

2.  Development and validation of a high-performance liquid chromatography assay for voriconazole.

Authors:  Gennethel J Pennick; Martin Clark; Deanna A Sutton; Michael G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 3.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

4.  Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol.

Authors:  J Seidegård; M Simonsson; S Edsbäcker
Journal:  Clin Pharmacol Ther       Date:  2000-04       Impact factor: 6.875

5.  Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes.

Authors:  L Pichard; I Fabre; M Daujat; J Domergue; H Joyeux; P Maurel
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

Review 6.  CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development.

Authors:  Gang Luo; Thomas Guenthner; Liang-Shang Gan; W Griffith Humphreys
Journal:  Curr Drug Metab       Date:  2004-12       Impact factor: 3.731

7.  Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient.

Authors:  C Robatel; M Rusca; C Padoin; O Marchetti; L Liaudet; T Buclin
Journal:  J Antimicrob Chemother       Date:  2004-06-02       Impact factor: 5.790

8.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

Authors:  S J Roffey; S Cole; P Comby; D Gibson; S G Jezequel; A N R Nedderman; D A Smith; D K Walker; N Wood
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

9.  Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.

Authors:  Lynn Purkins; Nolan Wood; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

10.  CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.

Authors:  Gang Luo; Mark Cunningham; Sean Kim; Tim Burn; Jianrong Lin; Michael Sinz; Geraldine Hamilton; Christopher Rizzo; Summer Jolley; Darryl Gilbert; April Downey; Daniel Mudra; Richard Graham; Kathy Carroll; Jindong Xie; Ajay Madan; Andrew Parkinson; Dave Christ; Bernard Selling; Edward LeCluyse; Liang-Shang Gan
Journal:  Drug Metab Dispos       Date:  2002-07       Impact factor: 3.922
View more
  12 in total

Review 1.  Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome.

Authors:  Maria N Gamaletsou; Blandine Rammaert; Marimelle A Bueno; Brad Moriyama; Nikolaos V Sipsas; Dimitrios P Kontoyiannis; Emmanuel Roilides; Valerie Zeller; Roberta Prinapori; Saad J Taj-Aldeen; Barry Brause; Olivier Lortholary; Thomas J Walsh
Journal:  J Infect       Date:  2013-12-27       Impact factor: 6.072

2.  What is the role of therapeutic drug monitoring in antifungal therapy?

Authors:  Jeannina A Smith
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

3.  What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis?

Authors:  Dimitrios P Kontoyiannis; David S Perlin; Emmanuel Roilides; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2013-05-06       Impact factor: 9.079

4.  Locally extensive angio-invasive Scedosporium prolificans infection following resection for squamous cell lung carcinoma.

Authors:  Natasha E Holmes; Janine M Trevillyan; Sarah E Kidd; Trishe Y-M Leong
Journal:  Med Mycol Case Rep       Date:  2013-04-19

5.  Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.

Authors:  M A Encalada Ventura; M J P van Wanrooy; L F R Span; M G G Rodgers; E R van den Heuvel; D R A Uges; T S van der Werf; J G W Kosterink; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

6.  Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.

Authors:  D Neofytos; D Ostrander; S Shoham; M Laverdiere; J Hiemenz; H Nguyen; W Clarke; L Brass; N Lu; K A Marr
Journal:  Transpl Infect Dis       Date:  2015-11-25       Impact factor: 2.228

7.  Inflammation is associated with voriconazole trough concentrations.

Authors:  Marjolijn J P van Wanrooy; Lambert F R Span; Michael G G Rodgers; Edwin R van den Heuvel; Donald R A Uges; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

8.  A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid.

Authors:  Nathan P Wiederhold; Gennethel J Pennick; Sheryl A Dorsey; Wieslaw Furmaga; James S Lewis; Thomas F Patterson; Deanna A Sutton; Annette W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

9.  Update on the optimal use of voriconazole for invasive fungal infections.

Authors:  Asma Lat; George R Thompson
Journal:  Infect Drug Resist       Date:  2011-02-03       Impact factor: 4.003

10.  A suspected case of autoinduction of voriconazole metabolism in a patient with cerebral aspergillosis.

Authors:  Martin J Ferguson; Maria L Randles; Declan G de Freitas
Journal:  Drug Healthc Patient Saf       Date:  2017-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.